Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 10 of 15
Long Acting Neuraxial Peri-prostatic Block in Cancer
Icahn School of Medicine at Mount Sinai
NCT06703437
Focal Laser Ablation of Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04305925
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
NCT05683964
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Praful Ravi, MB BCHir, MRCP
NCT05617885
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
M.D. Anderson Cancer Center
NCT06066437
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
Robert Flavell, MD, PhD
NCT05851365
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
SWOG Cancer Research Network
NCT00006392
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
NCT05202301
Continuation of Follow-up of DES-Exposed Cohorts
National Cancer Institute (NCI)
NCT00340600
Analyses of Human Samples Collected in Clinical Trials
National Cancer Institute (NCI)
NCT00339664
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
M.D. Anderson Cancer Center
NCT00453661
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
NCT00002597
Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making
University of North Carolina, Chapel Hill
NCT01558583
Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer
University of Colorado, Denver
NCT00830635
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
UNC Lineberger Comprehensive Cancer Center
NCT02564120
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Radiation Therapy Oncology Group
NCT00033631
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
AstraZeneca
NCT00617669
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
SWOG Cancer Research Network
NCT01809691
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Active Biotech AB
NCT01234311
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
GTx
NCT00129142
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development
NCT00887198
Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
NCT00002602
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Exelixis
NCT01605227
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Achieve Life Sciences
NCT01188187
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
NCT00004124
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Endocyte
NCT03511664
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
Bristol-Myers Squibb
NCT01057810
Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing
Myriad Genetic Laboratories
NCT03511235
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
SWOG Cancer Research Network
NCT00004001
Shared Decision Making: Prostate Cancer Screening
Lisa Richarson
NCT00207649
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
NCT00063882
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
VA Office of Research and Development
NCT01900561
CD-ROM Intervention for Prostate Cancer Screening
Centers for Disease Control and Prevention
NCT00164437
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
Alliance for Clinical Trials in Oncology
NCT00052481
Personal Patient Profile Prostate (P4) Randomized, Multisite Trial
Dana-Farber Cancer Institute
NCT00692653
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Rutgers, The State University of New Jersey
NCT01982058
Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
Gary Morrow
NCT00002848
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
Schiffler Cancer Center
NCT00241384
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Dana-Farber Cancer Institute
NCT01844999
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
National Cancer Institute (NCI)
NCT00002723
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America
NCT05605964
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Ferring Pharmaceuticals
NCT00451958
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
NCT00838201
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Astellas Pharma Global Development
NCT06500741
Genomics in Michigan Impacting Observation or Radiation
University of Michigan Rogel Cancer Center
NCT02783950
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
Bristol-Myers Squibb
NCT02985957
Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial
University of Washington
NCT06661902
Phase I/II Hypofractionated Radiotherapy for Prostate Cancer
University of Wisconsin, Madison
NCT00214097
Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting
Fox Chase Cancer Center
NCT01440855
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Alliance for Clinical Trials in Oncology
NCT00417040
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.